Patents by Inventor Waldemar Kolanus
Waldemar Kolanus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8163788Abstract: The invention relates to a pharmaceutical composition and the use thereof, wherein the pharmaceutical composition contains compounds selected from a group of general formulas (5), (6), (7) and (8) and/or enantiomers, diastereomers or the pharmaceutically acceptable salts thereof. The pharmaceutical composition is used for treating autoimmune and tumoral diseases and/or for immunosuppresion.Type: GrantFiled: November 18, 2005Date of Patent: April 24, 2012Assignee: Rheinische Friedrich-Wilhelms Universitat BonnInventors: Michael Famulok, Waldemar Kolanus, Markus Hafner, Imke Grune, Barbara Tappertzhofen, Mirko Theis
-
Publication number: 20110224279Abstract: The present invention relates to a nucleic acid molecule and a pharmaceutical or diagnostic composition for the therapeutic and/or prophylactic treatment or diagnosis of cancer and/or metastasis thereof, comprising a nucleic acid molecule, or an amino acid sequence related to Trim71 and/or its mammalian and non mammalian orthologs and/or a nucleic acid sequence of the gene encoding for Trim71 and/or its mammalian and non mammalian orthologs.Type: ApplicationFiled: February 27, 2009Publication date: September 15, 2011Applicant: RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITATInventors: Waldemar Kolanus, Michael Karl Hoch, Joachim L. Schultze, Birgit Loeer
-
Publication number: 20090105286Abstract: The invention relates to drugs and the use thereof, wherein said drugs contain compounds selected from a group comprising general formulas (1), (2), (3) and (4) and/or enantiomers, diastereomers or the pharmaceutically acceptable salts thereof. Said drugs are used for treating autoimmune and tumoral diseases and/or for immunosuppresion.Type: ApplicationFiled: November 18, 2005Publication date: April 23, 2009Applicant: Rheinische Friedrich-Wilhelms UniversitatInventors: Michael Famulok, Waldemar Kolanus, Markus Hafner, Imke Grune, Barbara Tappertzhofen, Mirko Theis
-
Patent number: 7320787Abstract: Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell. The chimeric receptor includes an extracellular portion which is capable of specifically recognizing and binding the target cell or target infective agent, and (b) an intracellular portion of a protein-tyrosine kinase which is capable of signalling the therapeutic cell to destroy a receptor-bound target cell or a receptor-bound target infective agent. Also disclosed are cells which express the chimeric receptors and DNA encoding the chimeric receptors.Type: GrantFiled: May 20, 2002Date of Patent: January 22, 2008Assignee: The General Hospital CorporationInventors: Brian Seed, Charles Romeo, Waldemar Kolanus
-
Publication number: 20070287153Abstract: Described are methods for the identification and validation of (1) functional intracellular targets and (2) nucleic acids (intramers) which are capable of binding to and modifying the function of said intracellular targets. These nucleic acids or, alternatively, compounds showing the same or a similar target specificity and/or effect are useful for the preparation of therapeutics, particularly for gene therapy.Type: ApplicationFiled: May 25, 2006Publication date: December 13, 2007Inventors: Michael Blind, Michael Famulok, Waldemar Kolanus
-
Patent number: 7094599Abstract: Disclosed is a method of directing a cellular immune response against an HIV-infected cell in a mammal involving administering to the mammal an effective amount of therapeutic cells which express a membrane-bound, proteinaceous chimeric receptor comprising (a) an extracellular portion which includes a fragment of CD4 which is capable of specifically recognizing and binding the HIV-infected cell but which does not mediate HIV infection and (b) an intracellular portion which is capable of signalling the therapeutic cell to destroy the receptor-bound HIV-infected cell. Also disclosed are cells which express the chimeric receptors and DNA and vectors encoding the chimeric receptors.Type: GrantFiled: August 24, 2001Date of Patent: August 22, 2006Assignee: The General Hospital CorporationInventors: Brian Seed, Babak Banapour, Charles Romeo, Waldemar Kolanus
-
Patent number: 7049136Abstract: Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell. Also disclosed are cells which express the chimeric receptors and DNA encoding the chimeric receptors.Type: GrantFiled: February 2, 1999Date of Patent: May 23, 2006Assignee: The General Hospital CorporationInventors: Brian Seed, Charles Romeo, Waldemar Kolanus
-
Patent number: 6753162Abstract: Disclosed is a method of directing a cellular immune response against an HIV-infected cell in a mammal involving administering to the mammal an effective amount of therapeutic cells which express a membrane-bound, proteinaceous chimeric receptor comprising (a) an extracellular portion which includes a fragment of CD4 which is capable of specifically recognizing and binding the HIV-infected cell but which does not mediate HIV infection and (b) an intracellular portion which is capable of signalling the therapeutic cell to destroy the receptor-bound HIV-infected cell. Also disclosed is a second method of treating HIV in a mammal involving administering to the mammal an effective amount of therapeutic cells expressing a membrane-bound, proteinaceous chimeric receptor comprising an extracellular portion which includes a fragment of CD4 which is capable of specifically recognizing and binding the HIV-infected cell but which does not mediate HIV infection.Type: GrantFiled: February 24, 1995Date of Patent: June 22, 2004Assignee: The General Hospital CorporationInventors: Brian Seed, Babak Banapour, Charles Romeo, Waldemar Kolanus
-
Publication number: 20040029775Abstract: The invention relates to the use of &bgr;3-endonexin-long or &bgr;3-endonexin-short for finding active substances for the treatment of arteriosclerosis, unstable plaques resulting from the latter, acute coronary thrombosis, cardiac infarct, stroke, peripheral arterial occlusion diseases, chronic venous ulcer and restenosing processes.Type: ApplicationFiled: July 1, 2003Publication date: February 12, 2004Inventors: Meinrad Gawaz, Martin Ungerer, Waldemar Kolanus
-
Publication number: 20040005334Abstract: Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell. Also disclosed are cells which express the chimeric receptors and DNA encoding the chimeric receptors.Type: ApplicationFiled: February 2, 1999Publication date: January 8, 2004Inventors: BRIAN SEED, CHARLES ROMEO, WALDEMAR KOLANUS
-
Publication number: 20030138410Abstract: Disclosed is a method of directing a cellular immune response against an HIV-infected cell in a mammal involving administering to the mammal an effective amount of therapeutic cells which express a membrane-bound, proteinaceous chimeric receptor comprising (a) an extracellular portion which includes a fragment of CD4 which is capable of specifically recognizing and binding the HIV-infected cell but which does not mediate HIV infection and (b) an intracellular portion which is capable of signalling the therapeutic cell to destroy the receptor-bound HIV-infected cell. Also disclosed are cells which express the chimeric receptors and DNA and vectors encoding the chimeric receptors.Type: ApplicationFiled: August 24, 2001Publication date: July 24, 2003Inventors: Brian Seed, Babak Banapour, Charles Romeo, Waldemar Kolanus
-
Patent number: 6573362Abstract: Isolated cytohesin-PH peptides that can inhibit the beta-2 integrins from adhering, wherein the cytohesin-PH peptide has an amino acid sequence that comprises about a 140 amino acid domain from cytohesin-2. Assay kits comprising the peptides also are provided.Type: GrantFiled: September 5, 1996Date of Patent: June 3, 2003Assignee: Hoechst AktiengesellschaftInventors: Waldemar Kolanus, Britta Ostner
-
Publication number: 20030053994Abstract: Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell. The chimeric receptor includes an extracellular portion which is capable of specifically recognizing and binding the target cell or target infective agent, and (b) an intracellular portion of a protein-tyrosine kinase which is capable of signalling the therapeutic cell to destroy a receptor-bound target cell or a receptor-bound target infective agent. Also disclosed are cells which express the chimeric receptors and DNA encoding the chimeric receptors.Type: ApplicationFiled: May 20, 2002Publication date: March 20, 2003Inventors: Brian Seed, Charles Romeo, Waldemar Kolanus
-
Publication number: 20020176851Abstract: Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell. The chimeric receptor includes an extracellular portion which is capable of specifically recognizing and binding the target cell or target infective agent, and (b) an intracellular portion of a protein-tyrosine kinase which is capable of signalling the therapeutic cell to destroy a receptor-bound target cell or a receptor-bound target infective agent. Also disclosed are cells which express the chimeric receptors and DNA encoding the chimeric receptors.Type: ApplicationFiled: February 25, 2002Publication date: November 28, 2002Inventors: Brian Seed, Charles Romeo, Waldemar Kolanus
-
Patent number: 6410014Abstract: Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell. The chimeric receptor includes an extracellular portion which is capable of specifically recognizing and binding the target cell or target infective agent, and (b) an intracellular portion of a protein-tyrosine kinase which is capable of signalling the therapeutic cell to destroy a receptor-bound target cell or a receptor-bound target infective agent. Also disclosed are cells which express the chimeric receptors and DNA encoding the chimeric receptors.Type: GrantFiled: June 15, 1999Date of Patent: June 25, 2002Assignee: The General Hospital CorporationInventors: Brian Seed, Charles Romeo, Waldemar Kolanus
-
Patent number: 6392013Abstract: Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell. The chimeric receptor includes an extracellular portion which is capable of specifically recognizing and binding the target cell or target infective agent, and (b) an intracellular portion of a protein-tyrosine kinase which is capable of signalling the therapeutic cell to destroy a receptor-bound target cell or a receptor-bound target infective agent. Also disclosed are cells which express the chimeric receptors and DNA encoding the chimeric receptors.Type: GrantFiled: July 7, 1997Date of Patent: May 21, 2002Assignee: The General Hospital CorporationInventors: Brian Seed, Charles Romeo, Waldemar Kolanus
-
Patent number: 6284240Abstract: Disclosed is a method of directing a cellular immune response against an HIV-infected cell in a mammal involving administering to the mammal an effective amount of therapeutic cells which express a membrane-bound, proteinaceous chimeric receptor comprising (a) an extracellular portion which includes a fragment of CD4 which is capable of specifically recognizing and binding the HIV-infected cell but which does not mediate HIV infection and (b) an intracellular portion which is capable of signalling the therapeutic cell to destroy the receptor-bound HIV-infected cell. Also disclosed are cells which express the chimeric receptors and DNA and vectors encoding the chimeric receptors.Type: GrantFiled: December 22, 1998Date of Patent: September 4, 2001Assignee: The General Hospital CorporationInventors: Brian Seed, Babak Banapour, Charles Romeo, Waldemar Kolanus
-
Patent number: 6004811Abstract: Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell. The chimeric receptor includes an extracellular portion which is capable of specifically recognizing and binding the target cell or target infective agent, and (b) an intracellular portion of a protein-tyrosine kinase which is capable of signalling the therapeutic cell to destroy a receptor-bound target cell or a receptor-bound target infective agent. Also disclosed are calls which express the chimeric receptors and DNA encoding the chimeric receptors.Type: GrantFiled: February 24, 1995Date of Patent: December 21, 1999Assignee: The Massachussetts General HospitalInventors: Brian Seed, Charles Romeo, Waldemar Kolanus
-
Patent number: 5912170Abstract: Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell. The chimeric receptor includes an extracellular portion which is capable of specifically recognizing and binding the target cell or target infective agent, and (b) an intracellular portion of a protein-tyrosine kinase which is capable of signalling the therapeutic cell to destroy a receptor-bound target cell or a receptor-bound target infective agent. Also disclosed are cells which express the chimeric receptors and DNA encoding the chimeric receptors.Type: GrantFiled: February 24, 1995Date of Patent: June 15, 1999Assignee: The General Hospital CorporationInventors: Brian Seed, Charles Romeo, Waldemar Kolanus
-
Patent number: 5851828Abstract: Disclosed is a method of directing a cellular immune response against an HIV-infected cell in a mammal involving administering to the mammal an effective amount of therapeutic cells which express a membrane-bound, proteinaceous chimeric receptor comprising (a) an extracellular portion which includes a fragment of CD4 which is capable of specifically recognizing and binding the HIV-infected cell but which does not mediate HIV infection and (b) an intracellular portion which is capable of signalling the therapeutic cell to destroy the receptor-bound HIV-infected cell. Also disclosed are cells which express the chimeric receptors and DNA and vectors encoding the chimeric receptors.Type: GrantFiled: August 2, 1994Date of Patent: December 22, 1998Assignee: The General Hospital CorporationInventors: Brian Seed, Babak Banapour, Charles Romeo, Waldemar Kolanus